Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
Healthcare
$30.51 +5.50%
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
52W Low $18.85High $27.20
Volume 0.53M
Average 0.38M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$53.61M
FY 2025 · Annual
Investing Cash Flow
$46.18M
FY 2025 · Annual
Financing Cash Flow
$10.84M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (29.82M) |
| Depreciation & Amortization | 3.86M |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.87M |
| Change in Working Capital | (32.57M) |
| Accounts Receivables | (5.5M) |
| Inventory | (23.78M) |
| Accounts Payables | (572K) |
| Other Working Capital | (2.72M) |
| Other Non-Cash Items | 2.05M |
| Operating Cash Flow | (53.61M) |
| Capital Expenditures | (6.38M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (4.94M) |
| Sales of Investments | 57.5M |
| Other Investing Activities | (1.01M) |
| Investing Cash Flow | 46.18M |
| Debt Repayment | 10M |
| Common Stock Issued | 1.49M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (657K) |
| Financing Cash Flow | 10.84M |
| Effect of Forex Changes | (172K) |
| Net Change in Cash | 3.23M |
| Free Cash Flow | (59.99M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$29.8M
+ D&A$3.9M
+ Stock-Based Comp$2.9M
+ Deferred Tax$0
- Working Capital-$32.6M
+ Other Non-Cash$2.0M
= Operating Cash Flow-$53.6M
- Capex-$6.4M
= Free Cash Flow-$60.0M
Analysis
FY2025 free cash flow is -$60.0M. FCF conversion is 201.2% of net income. Operating cash flow was -$53.6M, with capex of -$6.4M. The largest bridge item is Working Capital at -$32.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 |
Does ALMR generate free cash flow?
Alamar Biosciences, Inc. (ALMR) generated -$59.99M of free cash flow in fiscal 2025.
How much operating cash flow does ALMR produce?
Operating cash flow was -$53.61M, before capital expenditures of $6.38M.
Continue the stock analysis
Jump to another research area for this company.